Merck announced that its Phase 3 KEYNOTE-C93 trial for KEYTRUDA met its primary endpoint, delivering progression-free survival (PFS) benefits in patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer. The topline success supports the clinical efficacy thesis and is a positive catalyst for the program’s regulatory pathway.
Merck announced that its Phase 3 KEYNOTE-C93 trial for KEYTRUDA met its primary endpoint, delivering progression-free survival (PFS) benefits in patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer. The topline success supports the clinical efficacy thesis and is a positive catalyst for the program’s regulatory pathway.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.45
Ticker Sentiment
